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Abstract
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset neuromuscular disorder
characterised by selective loss of motor neurons leading to fatal paralysis. Current therapeutic
approaches are limited in their effectiveness. Substantial advances in understanding ALS dis-
ease mechanisms has come from the identification of pathogenic mutations in dominantly
inherited familial ALS (FALS). We previously reported a coding mutation in D-amino acid oxi-
dase (DAOR199W) associated with FALS. DAO metabolises D-serine, an essential co-agonist
at the N-Methyl-D-aspartic acid glutamate receptor subtype (NMDAR). Using primary motor
neuron cultures or motor neuron cell lines we demonstrated that expression of DAOR199W, pro-
moted the formation of ubiquitinated protein aggregates, activated autophagy and increased
apoptosis. The aim of this study was to characterise the effects of DAOR199W in vivo, using
transgenic mice overexpressing DAOR199W. Marked abnormal motor features, e.g. kyphosis,
were evident in mice expressing DAOR199W, which were associated with a significant loss
(19%) of lumbar spinal cord motor neurons, analysed at 14 months. When separated by
gender, this effect was greater in females (26%; p< 0.0132). In addition, we crossed the
DAOR199W transgenic mouse line with the SOD1G93A mouse model of ALS to determine
whether the effects of SOD1G93A were potentiated in the double transgenic line (DAOR199W/
SOD1G93A). Although overall survival was not affected, onset of neurological signs was signifi-
cantly earlier in female double transgenic animals than their female SOD1G93A littermates
(125 days vs 131 days, P = 0.0239). In summary, some significant in vivo effects of DAOR199W
on motor neuron function (i.e. kyphosis and loss of motor neurons) were detected which were
most marked in females and could contribute to the earlier onset of neurological signs in dou-
ble transgenic females compared to SOD1G93A littermates, highlighting the importance of rec-
ognizing gender effects present in animal models of ALS.
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Introduction
Amyotrophic lateral Sclerosis (ALS) is the most common adult-onset neuromuscular disorder,
caused by the selective degeneration of motor neurons in the spinal cord, brain stem and
motor cortex. The disease usually progresses rapidly leading to severe motor disability with
most patients dying within 3–5 years of diagnosis. Understanding the pathogenic mechanisms
that underlie the disease has been greatly accelerated by the identification of mutations that
cause the familial form of the disease (FALS) [1]. To date at least twenty genes have been
found that harbour mutations associated with FALS. The most prevalent mutations are found
in C9ORF72, SOD1, TAR DNA binding protein 43 (TARDBP), and Fused in Sarcoma (FUS) and
much evidence is accumulating to link these mutations with the classical neuropathological
features of both familial and sporadic forms of the disease i.e. the accumulation of cytosolic
ubiquitinated protein inclusions, most of which are positive for TDP-43 encoded by TARDBP
[2]. Interestingly, it has emerged from these genetic studies that dysfunction of two major
pathways are strongly associated with ALS pathogenesis. These effects are firstly focussed on
components of RNA metabolism, through dysfunction of the regulatory properties of RNA
binding proteins affecting splicing and their trafficking between the nucleus and cytosol and
secondly proteostasis, affecting the endoplasmic reticulum stress response and protein degra-
dation pathways mediated through the proteasome and autophagy [3]. A less well established
area is the understanding of trigger factors that initiate this process which potentially could
include glutamate excitotoxicity, impaired calcium homeostasis and oxidative stress.
Recently, our group identified a mutation in the D-amino acid oxidase gene (DAO) that was
transmitted with disease [4], a substitution of arginine by tryptophan at codon 199 (DAOR199W),
which has shed some light on more upstream events that may trigger disease initiation [4–6]. The
selective distribution of the protein in spinal cord and brain stem nuclei suggests a previously
unrecognised role for DAO in motor pathways and function [4]. The major function known for
DAO is the regulation of the levels of D-serine, which has a fundamental role in excitatory path-
ways as a co-agonist at the N-Methyl-D-aspartic acid (NMDA) glutamate receptor (NMDAR).
This important function of D-serine has now been well characterised and is known to be essential
in mediating some actions of glutamate in synaptic plasticity e.g. long term potentiation [7–10].
Furthermore, we have shown that expression of DAO containing the mutation associated with
FALS, DAOR199W, in primary motor neuron cultures or motor neuron cell lines promotes the for-
mation of ubiquitinated protein aggregates, activates autophagy and increases apoptosis. Impor-
tantly, we have shown that these effects can be significantly attenuated by a selective antagonist at
the D-serine binding site of the NMDA receptor, using a co-culture system where glial cells
expressing DAOR199W are incubated in an insert placed above motor neuron cells lacking the
mutation, which recapitulates the effects of the mutation on autophagy and apoptosis in the co-
cultured motor neuron cells [6]. In addition, DAOR199W leads to impaired enzymatic DAO
enzyme activity in ALS cases carrying the mutation and also when expressed in cell lines [4].
Interestingly, studies of a mouse strain (ddY/DAO−)[11] lacking DAO enzyme activity, due
to a naturally occurring point mutation at position 181 leading to the substitution of glycine
by arginine, revealed that while these animals grow and reproduce normally they exhibit
abnormal NMDA receptor-mediated behavour [12]. Furthermore a homozygous mouse line
expressing this mutation was generated (DAO-/-) that developed an abnormal limb reflex and
a significant loss of motor neurons in lumbar spinal cord at 8 months [13]. The study also
showed that both in this transgenic line and in the SODG93A mouse model of ALS, D-serine
accumulated in the spinal cord during disease progression and a marked suppression in DAO
activity was seen in the reticulospinal tract, a pathway that plays an important role in regulat-
ing motor neuron excitability [13].
In vivo effects of expression of the ALS-associated mutation, DAOR199W
PLOS ONE | https://doi.org/10.1371/journal.pone.0188912 December 1, 2017 2 / 22
Competing interests: The authors have declared
that no competing interests exist.
The aim of this study was to determine whether the deleterious effects of DAOR199W on
motor neurons detected in cell culture could be seen in vivo in transgenic mice overexpressing
DAOR199W. In addition, we crossed the DAOR199W transgenic mouse line with the SOD1 mouse
model of ALS to generate double transgenic mice expressing both mutations (DAOR199W/
SODG93A) to determine whether their effects were synergistic. We found that significant motor
neuron loss occurred in DAOR199W transgenic mice but the presence of DAOR199W in double
transgenic mice (DAOR199W/SODG93A) did not potentiate the effects of SOD1 over-expression on
survival.
Results
Generation of a new line of transgenic animals overexpressing
DAOR199W
Two independent lines were generated and upon successful transmission, transgene expres-
sion was confirmed in spinal cord using western blot analysis (Fig 1A) and extended to a wider
range of tissues (Fig 1B). As DAOR199W protein was under the influence of the CAGG pro-
moter/enhancer construct (beta actin promoter with the CMV enhancer), widespread expres-
sion in many tissues was seen. The highest levels of DAO expression were found in muscle and
heart, followed by kidney, spinal cord and brain, under conditions where endogenous levels of
DAO were low or undetectable. Quantitative PCR using selective primer sets that detect
expression of the human DAO transgene in DAOR199W transgenic mice indicated that the
DAOR199W transgene was present at concentrations 40-fold greater than that of mouse DAO
in the same animals (Fig 1C). In keeping with protein detection by Western blot analysis, the
DAOR199W transgene was markedly over-expressed in spinal cord compared to wild-type con-
trols and was present at even greater levels in skeletal muscle and heart. We also investigated
DAO activity in DAOR199W transgenic mice compared to control littermates using the peroxi-
dase-linked colorimetric conversion of ortho-dianisidine (protocol modified from Tedeschi
et al)[14] and found a mild reduction in overall enzyme activity in the brain and spinal cord,
suggesting that a degree of hetero-dimerisation with endogenous protein may occur (Figure A
in S1 File). No enzyme activity was detected in the muscle of wild-type and transgenic mice
despite substantial expression at the mRNA level in the transgenic mice.
DAO immunoreactivity was abundant in DAOR199W transgenic mice compared to control
littermates (Fig 1D) being present in large motor neurons and the surrounding grey matter of
ventral spinal cord. Similarly, ubiquitin immunoreactivity was high in grey matter of the ven-
tral spinal cord in DAOR199W mice, being most abundant in the cell bodies of large motor neu-
rons. In contrast, levels of ubiquitin were only present at low levels in controls (Fig 1D),
confirming previous studies in NSC-34 cell lines overexpressing DAOR199W compared to
DAOWT where it was established that a prominent feature of the cells expressing the mutant
DAOR199W allele was the presence of ubiquitinated protein aggregates [4].
Characterisation of the DAOR199W transgenic line: Effect on body weight
and morphological phenotype
Initially, we carried out a longitudinal large cohort survival study over a period of one year,
during which time body weight, motor features and gait were monitored. The assessor was
blinded to the genotype of the animals. Animals expressing the transgene consistently had a
lower body weight at each age compared to their wild type littermates, which was evident in
both males and females (Fig 2A and 2B).
In vivo effects of expression of the ALS-associated mutation, DAOR199W
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We observed some substantial and distinct features present in DAOR199W animals in terms
of physical appearance that were absent from wild-type littermates (Fig 3A). All males and
females bearing the mutant transgene appeared very hunched and developed progressive
kyphosis, which was more conspicuous in transgenic females than the males.
Fig 1. Transgene expression in two mouse lines (A), regional tissue expression of DAO protein (B) and mRNA (C) in DAOR199W transgenic mice
and immunohistochemical localisation of DAO and ubiquitin in DAOR199W Transgenic mice (D). A. Expression of DAO in spinal cord from two
DAOR199W lines. Western blot analysis of different transgenic mouse lines expressing human DAO. 200ng of spinal cord from each animal was separated by
SDS-PAGE and blotted with anti-DAO antibody. Expression of DAO was present in two DAOR199W transgenic mice lines, 12 and 34 (used in the survival
analysis). A porcine DAO protein standard (indicated by a + sign) was loaded in the final well. B. Regional expression of DAO protein in DAOR199W
transgenic mice. The highest concentrations of DAO (37kDa) in DAOR199W transgenic mice (indicated by +) were found in heart and quadriceps muscle
(upper panel), followed by kidney, spinal cord, brain (lower panel) and in both lines (shown here for line 34) compared to wild-type mice (indicated by a -).
Lower levels were found in liver and small intestine. The loading control was beta tubulin (50kDa). DAO immunoreactivity was low in non-transgenic mice. C.
Regional expression of DAO mRNA in DAOR199W transgenic mice. Expression of human DAO (hDAO) and mouse DAO (mDAO) in spinal cord, brain and
quadriceps muscle from wild-type (WT) and DAOR199W transgenic mice (R199W tg). D. Spinal cord expression of DAO and ubiquitin in DAOR199W
Transgenic mice. Lumbar spinal cord sections (L2-L4) from 8 month old non-transgenic and R199W DAO tg mice were immunostained for DAO and
ubiquitin and counterstained with Nissl (blue). Ventral horns with their enlargement (boxed area) are shown for each section. Spinal cord sections from the
DAOR199W transgenic showed widespread distribution of DAO staining (brown) throughout the ventral grey matter (lower left hand panel) particularly in
dendrites and interneurons with lower levels present in non-transgenic littermates (upper left hand panel). Similarly, ubiquitin staining was more intense in
sections from DAOR199W transgenic mice (lower right hand panel) compared to their non-transgenic littermates (upper right hand panel). Scale bar, 500um.
https://doi.org/10.1371/journal.pone.0188912.g001
In vivo effects of expression of the ALS-associated mutation, DAOR199W
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Characterisation of the DAOR199W transgenic line: Effect on motor
neuron populations
The effect of the DAOR199W mutation on motor neuron cell survival was investigated in the
DAOR199W transgenic line by quantification of the motor neurons in the lumbar region of
the spinal cord at the age of 14 months (13.5 to 14.5 months, Fig 3B and 3C). The quantifica-
tion of the ventral horn motor neurons (L3-L5) of the transgenic animals versus their wild
type littermates (n 5 per genotype, per sex) revealed a significant reduction in motor neuron
numbers in mice carrying the mutant allele in comparison to their wild type littermates. When
Fig 2. Longitudinal assessment of body weight in DAOR199W and wild-type littermates. Mean group body
weight plotted over time from 30 days to 350 days of age. (A) females, n = 23 DAOR199W (blue) and (n = 17) non-
transgenic littermates (black). (B) males, n = 15 DAOR199W (purple) and (n = 16) non-transgenic littermates (orange).
Values are means± SEMs.
https://doi.org/10.1371/journal.pone.0188912.g002
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separated according to gender, this decrease (25.7%) was significant in females (P = 0.0132)
though not in males (16.5% reduction).
Characterisation of the DAOR199W transgenic line: Gait analysis
The phenotypic difference between the wild type and mutant animals led us to design a gait
analysis experiment. In this study, we analysed both genotypes for their gait, footfall, and
mechanics covering over 40 parameters but observed no significant differences in gait and
body movement between DAOR199W animals and their wild type littermates. A significant
Fig 3. Phenotype of R199W DAO mouse showing (A) Kyphosis, (B) motor neuron loss in lumbar spinal cord, (C) ChAT immunohistochemisty in
lumbar spinal cord (D) Assessment of various gait indices in the hindlimbs of female DAOR199W and wild-type littermates. (A) Kyphosis of the spine
demonstrated in both male and female DAOR199W transgenic lines. The arrow denotes kyphosis of the spine. (B) Motor neuron counts in wildtype and R199W
DAO mice aged 14–15 months. Lumbar motor neurons in regions L3-L5 were stained with anti-ChAT antibody and every third section quantified for both male
and female wildtype and R199W DAO mice. The number of motor neurons in R199W DAO mice was reduced by 19.7% compared to wild-type mice (one-tailed,
unpaired t-test, *p<0.05). When split by gender, motor neuron loss was significantly reduced by 25.7% in females (p = 0.0132*, one-tailed, unpaired t-test) but in
males the reduction was by 16.5%, which was not significant. Histograms show means for 40 sections per animal ±SEM. (C) ChAT immunohistochemistry of L4
and L5 regions of a wild-type and transgenic animal with a DAOR199W mutation. Immunohistochemistry was performed on the lumbar spinal cord using anti-
ChAT on 20μm sections of spinal cord. (A) Wild-type female L4 and L5 sections. (B) Female with DAO R199W mutation L4 and L5 sections. The number of
ChAT-stained motor neurons in the female mice was 25.7% lower for the transgenic group compared to the wild-type group. (D) Assessment of various gait
indices in the hind-limbs of female DAOR199W and wild-type littermates. Mean groups combined, plotted for hind-limbs of the DAOR199W (black bars) and WT
(white bars) female mice. This was done through averaging the individual values generated by the DigiGait system for each hind-limb of a particular animal
(n 10 per experimental group). Stride (sum of stance and swing), stance (weight bearing portion of the stride in which the paw remains in contact with the belt),
swing (when the paw is not in contact with the belt) presented in the top panel, with P values of 0.5238, 0.7560 and 0.273 respectively (two-tailed, unpaired t-test,
P < 0.05). Brake (time intervals between initial and maximal paw contacts with the belt), paw angle (angle of the hind-paw during peak stance in relation to the
long axis of the body) and paw area at peak stance (maximal paw area in contact with the treadmill during the stance phase) presented in the bottom panel, with
P values of 0.4509, 0.0435*, 0.0673 respectively (Mann-Whitney test carried out for brake time and two-tailed, unpaired t-test for the other two parameters,
P < 0.05). Asterisk indicates a significant difference in term of the degree of paw angle between WT controls and DAOR199W mice. Values are standard error of
the mean (±SEM).
https://doi.org/10.1371/journal.pone.0188912.g003
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difference was however observed in terms of hind-paw angle in the DAOR199W transgenic
females (P = 0.0435, n 10) (Fig 3D). Paw angle is defined as the angle of the paw (hind or
fore) during peak stance in relation to the long axis of the body. Hence, a negative value for
this parameter indicates that the animal places its paw inward towards the long axis of its body
every time the paw is placed on the surface of the treadmill, and a positive value is an indica-
tion of the paws being placed outwards away from the long axis of the body [15–17].
The DAOR199W females place their hind-paws in a straight line, almost parallel to the long
axis of their bodies (mean value of angle, -0.008333 ± 0.7330˚) in comparison to their wild type
littermates (mean value of angle,-2.255 ± 0.7275˚). The data obtained for the same parameter
for the forepaws suggested that in order to maintain balance due the changes in the paw angle,
the animal was forced to turn its forepaws inwards, giving a mean value of -1.241 ± 0.5678˚,
compared to -0.005000 ± 0.5485˚ in wild type littermates (forepaws almost parallel to the body
axis) (Fig 3D). These differences may reflect an adaptation to weight loss, muscle atrophy and
skeletal changes.
In summary, while no overt ALS phenotype was evident in mice expressing DAOR199W,
marked structural and abnormal motor features were evident which were associated with a sig-
nificant loss of lumbar motor neurons. While a mutation can cause a lethal disease in humans,
it may not be possible to trigger the same phenotype in a transgenic mouse models carrying
the same mutation, as seen for VAPB mutations [18], and hence we investigated whether the
DAOR199W mutation would potentiate the effects of the SOD-1 mouse model of ALS.
DAOR199W and SOD1G93A survival study
Given the well-known nature of the SOD1G93A mouse model and its well-defined lifespan, we
examined the effect of the DAOR199W mutation on survival of SOD1G93A mice in a longitudi-
nal large cohort survival study to see if the mutant DAO increased the rate of disease develop-
ment and progression. Thus we crossed heterozygous DAOR199W females with SOD1G93A
male transgenic mice. Animals with SOD1G93A and DAOR199W/SOD1G93A genotypes were
recruited in the survival study, where the operator was blind to the genotype of each mouse.
The development of ALS related disabilities in both genotypes was assessed twice a week using
a neurological scoring system (with a scale of 0 to 4, where 0 was normal and four represented
complete paralysis of both hind-limbs) commencing from 30 days of age in conjunction with
the assessment of body weight [19]. The end point was established as the time at which the
mouse was unable to right itself within 20 seconds when placed on its side and at this stage the
animal was culled and the final age and weight recorded [19, 20].
Assessment of body weight demonstrated the expected gender differences, male animals
being heavier in terms of total body weight compared to their female littermates. Both geno-
types, SOD1G93A and DAOR199W/SOD1G93A, increased weight steadily until all animals
reached the maximum peak weight at approximately 88 days for males and 99 days for females
(Fig 4A and 4B). After this point all animals experienced a marked decrease in their body
weight, which continued to the humane end point. The most notable difference between geno-
types was the decreased body weight seen in double transgenic female animals compared to
SOD1 mice at all stages up until the peak weight was attained.
Assessment of neurological scores
Analysis of neurological scores for both females and males demonstrates that both genotypes
appeared normal early in their lifespan and did not develop any abnormalities until approxi-
mately 70 days of age, after which neurological scores consistently worsened until the animals
reached the end stage. No significant differences were seen between the two genotypes (Fig 5).
In vivo effects of expression of the ALS-associated mutation, DAOR199W
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Further analysis of the neurological scores was carried out as previously described [21] to
yield values for onset of neurological signs, disease onset, disease progression and survival.
Fig 4. Longitudinal assessment of body weight in female SOD1G93A and double transgenic
(SOD1G93A/DAOR199W) littermates. Mean group body weight plotted for SOD1G93A and double transgenic
(SOD1G93A/DAOR199W) mice over time from approximately 30 days of age until all the animals within a group
reached the end stage and the study was terminated (n 14 per experimental group). As mice within groups
died at different ages, in order to avoid decomposition of the mean at later stages, the final weights of all mice
were carried forward when calculating group mean values, until the date at which the last mouse within each
group died. Values are means with the standard error of the mean (SEM) indicated by error bars. (A)
SOD1G93A females are presented in purple, and the double transgenic (SOD1G93A/DAOR199W) littermates are
displayed in red. (B) SOD1G93A males are presented in blue, and the double transgenic (SOD1G93A/
DAOR199W) littermates are displayed in green.
https://doi.org/10.1371/journal.pone.0188912.g004
In vivo effects of expression of the ALS-associated mutation, DAOR199W
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Fig 5. Longitudinal assessment of neurological scores in female SOD1G93A and double transgenic
(SOD1G93A/DAOR199W) littermates (A) and for male mice (B). Mean group combined neurological score
plotted for SOD1G93A and double transgenic (SOD1G93A/DAOR199W) mice over time from approximately 30 days
of age until all the animals within a group died and the study was terminated (n 14 per experimental group). A
combined neurological score was calculated for each mouse at each time point through summation of the
neurological scores recorded for its left and right hind-limbs. Values are means with standard error of the mean
(SEM) indicated by error bars. (A) SOD1G93A females are presented in purple, and the double transgenic
(SOD1G93A/DAOR199W) littermates are displayed in red. (B) SOD1G93A males are presented in blue, and the
double transgenic (SOD1G93A/DAOR199W) littermates are displayed in green.
https://doi.org/10.1371/journal.pone.0188912.g005
In vivo effects of expression of the ALS-associated mutation, DAOR199W
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Onset of neurological symptoms was defined as the point in time at which the animal reached
a score of 2 (displayed by toe curling or dragging any part of the foot). Double transgenic
females first displayed a neurological score of 2 at approximately 125 days of age, significantly
earlier (p = 0.0239) than their SOD1G93A littermates (~131 days). Double transgenic males
reached the score of 2 at approximately 119 days, which is slightly (but not significantly) later
than their SOD1G93A littermates (~113 days). In addition, comparison of the same genotypes
across the sexes indicate that while there were no differences in terms of the onset of neurolog-
ical symptoms between double mutant transgenic mice, there was a significant difference in
the time of onset between the SOD1G93A animals, with females exhibiting significantly later
onset than male littermates (Table 1).
Analysis of disease onset, defined as the point in time the animal was at its highest weight,
showed an earlier age of 89 days in males compared to females (99 days of age). Onset of dis-
ease in both SOD1G93A and double transgenic mice was very similar (Table 1). Progression of
disease, defined as the period of time between disease onset and the end stage, was very similar
across all groups, ranging from 39 to 42 days.
Survival time, defined as the period of time between birth and the humane end point, deter-
mined by the inability of the animal to right itself within 20 seconds of being placed on its side,
showed no major differences between the different genotypes and gender (Table 1), SOD1G93A
and the double transgenic mice lived for a median of 129 and 126 days respectively in males
and for 136 and 135 days respectively in females.
Comparison of the survival curves across the genotypes indicated that SOD1G93A females
had a longer average lifespan (136 days) than their SOD1G93A male littermates (129 days)
(Table 1) but these differences did not reach significance (P = 0.0771). Similar results were
obtained for the double transgenic animals, with females living significantly longer (median of
135 days, P = 0.0241) than their double transgenic male littermates (median of 126 days).
Table 1. Kaplan Meier time to event analyses for SOD1G93A and double transgenic (SOD1G93A/DAOR199W) in both males and females. A. Median val-
ues obtained from Kaplan-Meier analysis for the time taken for mice to reach a score of 2 in both hindlimbs (onset of neurological scores), age at maximum
weight (disease onset), disease progression and time taken for animals to reach the humane end point determined by its inability to right itself within 20 sec-
onds of being placed on its side (survival) for both males and female littermates of either genotype groups. B. The Log-rank test assesses the null hypothesis
that the Kaplan-Meier curves for all groups are identical (i.e. the presence of the DAOR199W transgene did not change the time taken to reach the event being
analysed). Thus, low P-values (shown below) indicate that differences between genotype groups did not occur due to chance. Log-rank analysis of the onset
of neurological symptoms in females carrying the SOD1G93A transgene versus their double transgenic littermates revealed that there were significant differ-
ences between the groups for this particular measurement. A significant difference was also detected in survival between the double transgenic males and
females via the log-rank test. Significant differences are indicated in bold. Threshold of significance was set at P < 0.05.
(A) Median (days)
SOD1G93A Double Transgenics (DT)
Males Females Males Females
Onset of Neurological Symptoms 113 131 119 125
Disease Onset 89 99 88 99
Disease Progression 42 41 39 42
Survival 129 136 126 135
(B) Log-Rank Test (P Value)
SOD1G93A DT DT vs. SOD1G93A
Males vs. Females Males vs. Females Males Females
Onset of Neurological Symptoms 0.0004 0.0518 0.3865 0.0239
Disease Onset 0.1102 0.1131 0.8183 0.7358
Disease Progression 0.5786 0.3318 0.2935 0.4750
Survival 0.0771 0.0241 0.2229 0.8242
https://doi.org/10.1371/journal.pone.0188912.t001
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Discussion
In this study we have characterized the in vivo effects of expression of a pathogenic mutation
in DAO that is associated with familial ALS [4]. In earlier studies in cell culture, we showed
that overexpression of DAOR199W promoted apoptosis in both primary motor neuron cultures
and the motor neuron cell line, NSC-34, whereas overexpression of the wild-type protein
DAOWT was without effect on cell survival. Other changes occurring in motor neurons
expressing the mutant protein included the formation of ubiqutinated protein aggregates and
substantial activation of autophagy [6]. Although these pathogenic effects may be mediated
primarily by the accumulation of the mutant protein, other factors may be relevant, such as
the impaired activity of DAO and consequential effects on D-serine metabolism. D-serine is a
co-agonist at the NMDA receptor playing an essential role in mediating excitatory activity in
the CNS. We showed that co-culturing motor neurons with glial cells expressing DAOR199W
was sufficient to induce apoptosis in motor neurons lacking the mutant protein and that this
effect was sensitive to 5,7-Dichloro-4-hydroxyquinoline-2-carboxylic acid (DCKA), an
NMDAR antagonist selective for the D-serine/glycine site [6]. The increased protein aggrega-
tion and upregulation of autophagy seen in motor neuron cell lines expressing DAOR199W
compared to cell lines expressing DAOWT were both also sensitive to this antagonist. These
results suggest that the pathogenic effects of DAOR199W may at least be partly mediated
through an excitotoxic mechanism, potentiated by the build-up of D-serine in the synapse.
The high levels of DAO found in human spinal cord and brain stem motor neurons are consis-
tent with the vital role played by DAO in preventing excitotoxic cell death in these regions.
In this study, we have generated transgenic mouse lines expressing the human DAO muta-
tion associated with FALS in order to characterise the effects of this mutation in vivo. We mon-
itored body weight, motor features, gait and quantified motor neurones in lumbar spinal cord
in transgenic lines expressing DAOR199W in a longitudinal large cohort survival study over a
period of one year to characterise effects on motor function. The most distinctive features seen
were decreased body weight, marked kyphosis and loss of motor neurons in spinal cord. All of
these features are characteristic of several ALS models including SOD1G93A transgenic mice
[22] and conditional targeted inactivation of the Tardbp gene in spinal cord motor neurons
[23]. In addition, recent studies of a naturally occurring mouse mutation in DAO [11]
DAOG181R [24], bred as a homozygous line exhibited marked effects on motor phenotype,
with abnormal reflexes characterised by retraction of hind limbs, as occurs in SOD1G93A mice,
accompanied by a significant reduction in motor neuron number, as occurred in this study in
DAOR199W mice, and axonal degeneration with muscle atrophy demonstrated at 15 months
[13].
Animals expressing the DAOR199W transgene consistently had a lower body weight at each
age compared to their wild type littermates (Fig 2), which was evident in both females and
males (Fig 2A and 2B). This clearly shows that impaired DAO activity affects normal weight
gain in heterozygous animals expressing the mutant protein in the presence of endogenous
mouse DAO. The decreased body weight is consistent with studies on ddY/DAO− mice that
lack DAO activity. When fed a diet in which L-phenylalanine was replaced by D-phenylala-
nine, these mice were unable to maintain their body weight compared to wild type animals
(ddY/DAO+) [25]. This study clearly shows that impaired DAO activity affects normal weight
gain both when given a D-amino acid enriched diet and also in our study on heterozygous ani-
mals expressing the mutant protein without D-amino acid enrichment but in the presence of
endogenous mouse DAO. Both males and females bearing the mutant transgene also devel-
oped progressive kyphosis, which was more conspicuous in transgenic females than the males.
This skeletal abnormality is also prominent in mouse models of ALS such as the SOD1 mouse
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carrying the human ALS mutation and may be a consequence of the weakening of the extensor
thoracic paraspinal muscles as suggested by Wu et al [23] and as seen in ALS patients [26].
Further studies of gait and body movement in DAOR199W animals demonstrated a significant
difference in terms of paw angle in the DAOR199W transgenic females in comparison to their
wild type littermates which is likely to have been a consequence of degenerative changes result-
ing from motor neuron loss and muscle atrophy.
Although D-serine was not quantified in tissue homogenates in transgenic animals in this
study, D-serine immunoreactivity was measured in lumbar spinal cord in transgenic and wild-
type littermates using a rabbit polyclonal anti-serine antibody raised against D-serine cross-
linked to bovine serum albumin with glutaraldehyde (Abcam, dilution 1:5,000), as previously
used to characterise D-serine distribution in human and mouse spinal cord [6], where the full
characterisation is described. Consistent with these studies, we found that D-serine immuno-
reactivity was predominantly concentrated in large motor neurons in transgenic mice and
their non-transgenic littermate (Figure B in S1 File). In addition, serine racemase was abun-
dant in spinal cord grey matter and strongly localised to large motor neurones (Figure C in S1
File).A similar distribution was seen in both wild-type and DAOR199W mice but this did not
reflect changes occurring in extracellular and non-neuronal compartments or in the relative
levels of D and L-serine. However, it is already known that D-serine is elevated in spinal cord
of sporadic cases of ALS and also in the SOD1 mouse model of ALS suggesting the involve-
ment of glutamate excitotoxicity in ALS pathogenesis [27]. Furthermore the same group also
showed that D-serine was significantly elevated in spinal cord tissue homogenates from the
DAOG183R homozygous mouse line at 5 months, using a sensitive and selective 2D-HPLC
method, but a significant increase was not detected in the heterozygous mouse line [13].
In summary, despite the development of motor defects, within the time frame of this study,
overall survival was not reduced in DAOR199W mice. This suggests that other factors must con-
tribute to the severe phenotype seen in ALS cases expressing this mutation. We therefore looked
to see if the presence of DAOR199W potentiated the development of disease in SOD1G93A trans-
genic mice by crossing the DAOR199W and SOD1G93A mouse lines to generate a double trans-
genic line (DAOR188W/SOD1G93A). A role for DAO in the pathogenicity of the SOD1G93A mouse
has already been demonstrated by the observation that DAO activity is decreased by 42%,
which is equivalent to the reduction seen in DAO heterozygote mice [13]. The effect of this
reduced DAO activity, measured using a sensitive 2D-HPLC method, was also confirmed to
result in the expected increase in levels of D-serine in spinal cord that increased with disease
progression [13].
Body weight and neurological scores were monitored twice a week and survival was deter-
mined as the age at which the animal was unable to right itself within 20 seconds of being
placed on its side. Overall, both the SOD1G93A and their double transgenic littermates followed
the same pattern in terms of their marked reduction in body weight after 90 days. However,
marked differences in body weight were seen between males and females (Fig 4). Whilst body
weight was lower in female double transgenic mice compared to SOD1G93A mice, in males
both SOD1G93A and double transgenic animals showed a similar body mass (Fig 4). This dif-
ferential effect in females may reflect an endocrine effect, as testosterone is known to stimulate
DAO activity in mouse kidney [28].
Since the DAOR199W transgenic line is heterozygous for the DAO allele on the C57B16xCBA/
Ca background, as well as expressing the mutant allele they also express the wild type endogenous
DAO protein. It has been demonstrated that DAO activity is significantly reduced in the lumbar
region of the SOD1G93A mice, to levels approaching those of the B6DAO+/− mice [13]. It is
thus likely that the effect of the endogenous DAO protein is suppressed by the presence of the
SOD1G93A transgene in our double transgenic animals. As DAO is required for degradation of
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D-amino acids, it is therefore possible that the presence of both the SOD1G93A and DAOR199W
mutant transgenes in the double transgenic females suppressed or diminished the already low
levels of endogenous DAO enzyme activity, preventing animals from maintaining their overall
body mass and consequently exhibiting a consistent reduction in weight when compared to
their SOD1G93A littermates throughout their lifespan (Fig 2). Conversely, the marked similarity in
body weight between the double transgenic males and their SOD1G93A littermates could stem
from the innately higher levels of DAO enzymatic activity found in males compared to females
which might buffer the influence of the double transgene, permitting a residual level of function
sufficient for the animals to maintain their body weight at a level comparable to their SOD1G93A
littermates. This low level of endogenous DAO enzyme activity could also account for the attenu-
ated motor neuron loss in the lumbar region of the spinal cord that we found in males which
(in contrast to the reduction observed in females) did not reach significance. This in turn may
be an indication of protective properties of the wild type DAO protein against motor neuron
degeneration.
Interestingly, onset of neurological symptoms in double transgenic mice also showed a dif-
ferential effect in males and females (Fig 5, Table 1). Most notably, while males of both geno-
types typically developed symptoms at earlier time points than females, female double
transgenic animals displayed a symptomatic onset six days earlier than their female SOD1G93A
littermates (125 days vs 131 days, P = 0.0239). No such potentiation was observed in male dou-
ble transgenic mice. Disease progression and survival appeared largely insensitive to the pres-
ence of the DAOR199W transgene, although double transgenic females did survive significantly
longer than double transgenic males (P = 0.0241).
In conclusion, our results indicate that although the different genotypes exhibit some clear
differences, overall the presence of the DAOR199W transgene alongside SOD1G93A did not
exert any major effects on disease onset, progression or survival in either sex. This is likely due
to the aggressive and accelerated nature of the phenotype enforced by the SOD1G93A mutation,
masking any effect the DAOR199W mutation may trigger. It is also important to point out that
in our initial characterization of the DAOR199W, we detected enhanced ubiquitination at 8
months (Fig 1C) and motor neuron cell loss at 14 months (13.5 to 14.5 months) (Fig 3C). Such
progressive changes would not have been well established within the time scale of the SOD1
pathology (which has onset at approximately 3 months with death occurring at 5 months). In
future it would be useful to carry out the DAOR199W cross with a lower copy number SOD1
mouse line.
Two recent studies have further supported the relevance of DAO dysfunction to ALS patho-
genesis. Firstly in a comprehensive exome sequencing study in 2,874 cases with sporadic ALS
and 6,405 controls, interestingly, it was shown that DAO was the only known predisposition
gene where the presence of DNA variants was significantly associated with clinical outcome,
decreasing rates of survival [29]. Secondly, in a study of the effect a pathogenic mutation in a
gene encoding an RNA binding protein, hnRNP A2/B2, that, in common with mutations in
the FALS gene VCP causes multisystem proteinopathy, it was found to have a profound effect
on the splicing of DAO [30]. The resulting abnormality was a decrease in the constitutive form
of DAO, the full length transcript analysed in this study (Fig 1), accompanied by an increase in
the level of a transcript lacking exon 9, that leads to truncation of the protein and severely
reduces enzyme activity. In future studies, it will be important to further elucidate whether the
formation of this alternative transcript contributes to the pathogenesis of ALS.
Materials and methods
All reagents purchased from Sigma unless indicated otherwise.
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Ethics statement
All animal experiments were carried out under license from the Home Office (UK) in accor-
dance with the Animals Scientific Procedures Act 1986 and were approved by Imperial College
London / Royal Veterinary College ethical review committees.
Establishment of the DAOR199W transgenic mouse line
Transgenic mouse lines overexpressing DAOR199W were created using human DAOR199W,
driven by a chicken β-actin promoter and cytomegalovirus enhancer, pCAGGS (Niwa et al.,
1991). The linearized transgene was microinjected into pronuclei of fertilized eggs from
C57BL6×CBA/Ca female mice, which were subsequently transferred to pseudopregnant recip-
ients. Integration of the transgene into the genomic DNA was determined 3–4 weeks after
birth, by collecting a small ear biopsy from the pups and screening for the transgene expression
by using polymerase chain reaction (PCR). Hemizygote colonies from two independent foun-
ders expressing the transgenes were established and maintained by crossing DAOR199W
males with wild-type F1 hybrid C57BL6xCBA/Ca females.
Survival studies
Two transgenic mouse lines were used, a widely used high copy number SOD1G93A and the
DAOR199W mouse lines, generated in this study. Mice overexpressing human SOD1 bearing
the G93A mutation causing a motor neuron phenotype [B6SJL-TgN SOD1G93A 1 Gur/J, Stock
number 002726] [31] were initially purchased from the Jackson Laboratory (Bar Harbor, ME).
They were maintained as hemizygotes by breeding male mice with wild type F1 hybrid
C57BL6xCBA/Ca females. The SOD1G93A mice have been generated on this background for
over 28 generations, and animals on this background have similar disease characteristics (as
previously assessed by hindlimb electrophysiological parameters [32, 33] and longitudinal
monitoring of neurological score and body weight [34, 35] and life span to the original and
more widely used B6SJL hybrid genetic background [36, 37]. We did not observe any changes
in terms of lifespan and disease progression in these animals with successive generations in
our laboratory [35, 38].
A double transgenic (DT) mouse model was generated following breeding of heterozygous
high copy number SOD1G93A males with heterozygous DAOR199W females, generating 4 dif-
ferent genotypes per cross. Genotypes obtained from the cross were SOD1G93A, SOD1G93A/
DAOR199W, DAOR199W, and Wild-type.
Genotyping. Genotyping was carried out following weaning, using an ear biopsy (~1.5-
3mm2 in size). DNA extraction was performed by overnight incubation of the samples at 55˚C
in 1x homogenisation ear biopsy buffer (50μl). After digestion, proteinase K (Invitrogen) was
inactivated at 100˚C and samples were screened for the expression of the transgenes of interest
(SOD1G93A or DAOR199W) using specific PCR conditions for each genotype as detailed in S1
File.
Design for survival studies. Based on the results of Scott et al [19] who defined the opti-
mal conditions for carrying out survival studies involving the SOD1G93A strain, we used 24
mice per experimental group per cohort (12 males and 12 females), same-gender litter match-
ing, and excluded any animal who had experienced loss of SOD1G93A transgene copy number
[19]. Disease onset and progression were established through a combination of longitudinal
monitoring of weight and neurological score [19, 34, 39]. Each individual animal was assessed
using a simple neurological scoring system, which provided a rapid, non-invasive and unam-
biguous measure of disease onset and progression in SOD1G93A mice [19, 34, 35, 38, 39].
Weight loss in high copy number SOD1G93A mice is normally a gradual process that begins at
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approximately 90 days of age and continues until death. Rapid losses of weight over a short
period of time that does not fit the normal pattern can therefore be indicative of non ALS
related problems [19]. In addition, based on the data generated from the previous survival
analyses in our laboratory we determined the end point as the inability of the animal to right
itself within 20 seconds of being placed on its side. From 100 days of age, the righting reflex of
each mouse was examined twice daily to ensure that the end point of each mouse was accu-
rately determined. Once mice reached the end point, they were euthanized via cervical disloca-
tion, the date and cause of their death were recorded and an ear and tail biopsy was collected
for PCR and Q-PCR respectively to reconfirm the genotype and for examination of SOD1G93A
transgene copy number, as changes in the latter affect disease progression and ultimately sur-
vival. SOD1G93A transgene copy number variation was assessed by quantitative PCR (qPCR)
in any animal demonstrating outlying disease progression or survival characteristics [40].
Animals participating in all the in vivo studies were housed in a minimal disease facility at
the Royal Veterinary College, with a ‘12:12’ hour ‘light:dark’ cycle, food and water ad libitum.
Breeding trios each consisting of one SOD1G93A transgenic male and two DAOR199W females
were set up simultaneously to generate a large cohort of age matched pups with a mixture of
genotypes namely SOD1G93A, DAOR199W, SOD1G93A/DAOR199W, and wild type, for enrolment
in the “SOD1G93A x DAOR199W” survival study. Littermates of the same sex were housed
together regardless of the genotype (not exceeding 5 animals per cage) to ensure consistency of
the results in terms of age and gender, and the assessor was blinded to the genotypes of the
individual mice until the termination of the study.
Survival study analysis. The development of ALS related disabilities were assessed by
means of neurological scoring system for both hind legs twice weekly for each mouse from
approximately 30 days of age in the case of “SOD1G93A x DAOR199W” cross. Neurological
scores were assigned using a scale of 0–4, established by the ALSTDI through detailed observa-
tions of SOD1G93A mouse pathology [19, 34, 39]. Criteria used to assign each score level were:
• 0: Full extension of hind legs away from lateral midline when mouse is suspended by its tail
and mouse can hold this for 2 seconds, suspended 2–3 times.
• 1: Partial or full collapse of leg extension towards lateral midline or trembling of hind legs
during tail suspension.
• 2: Toes curl under at least twice during walking of 12 inches or any part of foot is dragging
along cage bottom (a clean cage containing no bedding was used for this analysis to permit
easy viewing of the toes).
• 3: Minimal joint movement or rigid paralysis, foot not being used for forward motion.
• 4: Mouse cannot right itself within 20 seconds from one or both sides when placed on its
side.
Graphical representation & statistical analysis. In order to demonstrate overall changes
in body weight and neurological score, mean values for both body weight and neurological
score were plotted for each group over time until the point in time at which the last mouse in
the group reached the humane end point. To prevent decomposition of the mean weight and
neurological score values as mice reached the end point, final weight and neurological score
values for individual mice that reached the end point were carried forward until the time point
at which the last mouse in that particular group reached the humane end point. This is a prac-
tice commonly used when performing survival analyses with longitudinal monitoring of
weight and neurological score [34, 38, 39]. In order to avoid the loss of statistical validity that
In vivo effects of expression of the ALS-associated mutation, DAOR199W
PLOS ONE | https://doi.org/10.1371/journal.pone.0188912 December 1, 2017 15 / 22
can occur when performing repeated analyses on correlated serial measurements for the same
subjects, relevant summary measures for weight and neurological score data were selected as
advised by Matthews and colleagues and statistical analyses were performed on these summary
measures [21]. Summary measures selected include: time to attain peak weight (the earliest
indicator of disease onset), time from peak weight to death (an indicator of disease progres-
sion), time to attain a neurological score of 2 in both hind-limbs (defined as the onset of neu-
rological symptoms) and time to reach a score of 4 (the uniform humane end point selected
for this study). These summary measures all represent ‘time to event measures’ and were ana-
lysed via Kaplan-Meier survival analyses: the log-rank test was performed to determine the sta-
tistical significance amongst experimental groups with the null-hypothesis that presence of the
DAO transgene did not change the time taken to reach the event being analysed. A low P-value
thus indicates that the differences between the curves did not occur due to chance, with the
threshold for significance being set at (P < 0.05) for all analyses [38]. All Kaplan-Meier sur-
vival analyses were carried out using Graphpad Prism 6 software.
In the case of assessment of overall body weight, animals were weighed and values were
plotted as ‘mean group body weight’ at each particular age using Excel software. Since each
genotype group generated through the crosses was considered as a new strain of mice, and tak-
ing into account the fact that the differences in body weight commenced at birth, it was con-
cluded by our statistician advisor that differences in body weight between the different
experimental groups were not statistically comparable. Thus, no statistical test was carried out
for this particular variable.
Gait analysis. Upon completion of the SOD1G93A/DAOR199W survival study, animals
expressing the DAOR199W mutant transgene and their wild type littermates were recruited to a
gait analysis study carried out using the DigiGait Imaging System (Mouse Specifics, Inc.). An
automated system equipped with transparent treadmill belt and adjustable speed, and a video
camera mounted underneath the belt captured the image of the ventral side of the animals
automatically pixelating and vectorizing the ventral view of the animal [15]. The collected
images were automatically analysed via the DigiGait software (Mouse Specifics, Inc.) where
the area of each paw was recorded in correspondence to its movement and a periodic wave
curve was therefore generated describing the advance and retreat of the four limbs in compari-
son to the treadmill belt through consecutive strides [15]. The portions of the paw that were in
contact with the treadmill belt were automatically recognized as the stance phase of the stride
by the software and the portion of the paw not in contact with the treadmill belt were conse-
quently identified as the swing phase of the stride [15]. In addition, various other gait dynam-
ics (i.e. over 40 parameters) were determined for each individual limb by the software that
were extracted from the period of time spent in various portions of the walking phase, includ-
ing paw area at peak stance, paw angle, brake, swing, stride length, and stepping frequency
(Text A in S1 File).
Spinal cord collection & preparation. Animals were deeply anaesthetized by intraperito-
neal (IP) administration of pentobarbital (Merial, UK) overdose (approximately 120–150μl).
Under terminal anaesthesia the animals were subjected to transcardial perfusion with ice-cold
PBS and ice-cold 4% PFA (prepared in PBS) respectively. Upon completion of the perfusion
process, the spinal column was removed and post-fixed in 4% PFA at 4˚C overnight. The spi-
nal cord was then extracted from the spinal column and cryoprotected in 30% sterilized
sucrose solution (prepared in PBS) at 4˚C, a process that often required a few days during
which the spinal cord sank towards the bottom the container within the sucrose solution. The
lumbar region of the spinal cord was then selectively dissected, and embedded in gelatin and
mounted on a cork block held in place with Cryo M-bed (Bright). This process involved verti-
cally mounting the spinal cord on the cork block with the most caudal end placed on the cork
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block. The ventral side of the spinal cord was marked on the cork to allow orientation of the
block within the cryostat such that the ventral side met the knife first [37]. The mounted spinal
cord was then snap-frozen in liquid nitrogen cooled isopentane (Fisher Scientific) (-55˚C,
+/-5˚C) and stored at -80˚C.
Lumbar spinal cord sectioning. The lumbar regions of 23 mouse spinal cords were sec-
tioned using a cryostat (Bright, UK). Sections of 20μm were taken between the regions of
L2-L6. Sections were arranged on Superfrost miscroscope slides (VWR, Belgium). Slides with
sections were frozen at -80˚C pending analysis.
Staining of sections. Nissl staining of nucleic acids in the tissue was performed on every
6th slide to identify the L3 to L5 regions of the animals’ spinal cords. Sections were placed in
Nissl stain for 30 minutes before washing and dehydrating in graded alcohols before clearing
in xylene and mounting with coverslips and DPX mountant (Sigma-Aldrich). The L3 to L5
region for each animal was determined using a Leica DM2500 microscope and descriptions of
mouse spinal cord regions by Watson at al. [41]. The lumbar motor neuron pool starts at L3
and extends to L5 [42].
Immunohistochemistry for the enzyme ChAT was performed on every 2nd and 5th slide on
the L3 through to L5 regions of animals. After rehydrating with phosphate buffered saline with
0.1% Tween120 (Sigma-Aldrich) (PBS/T), endogenous peroxidase activity was quenched by
incubating sections in PBS/T with 0.3% hydrogen peroxide (Sigma-Aldrich) for 5 minutes.
Sections were then incubated with Avidin for 10 minutes and after washing with Biotin for 10
minutes, both from the Vector blocking kit (Vector, USA). Sections were washed again with
PBS/T and blocked with 5% bovine serum albumin (Sigma-Aldrich) (BSA) in PBS/T for 30
minutes. Slides were washed with PBS/T and sections were incubated with the primary anti-
body, anti-ChAT (Millipore, USA), at 1:100 in PBS/T with 1% BSA overnight at 4˚C.
After 3 x 5 minute washes with PBS/T sections were incubated in the secondary antibody,
biotinylated anti-goat (Vector) at 1:500 in PBS/T with 1% BSA for 1 hour. Vector ABC reagent
(Vector stain Elite kit) was made with 2 drops of solution A and 2 drops of solution B in 5ml
PBS/T and left at room temperature for 30 minutes and then put on ice for 30 minutes before
use. Sections were washed for 3 x 5 minutes with PBS/T and incubated in ABC reagent for 30
minutes. After 3 x 5 minute washes with PBS/T DAB solution was added made up using the
DAB peroxidase substrate kit (Vector) of 2 drops of buffer, 4 drops DAB and 2 drops of hydro-
gen peroxide in 5 ml of distilled water. After 2 minutes DAB was washed off with water and
dehydrated with graded alcohols before clearing in xylene for 2 x 10minutes. Slides were
mounted with DPX and 60mm coverslips.
Motor neuron counts. For the ChAT stained slides the motor neurons of every section
within the L3-L5 regions were counted. The motor neurons were counted that were identifi-
able in the structures of the lumbar ventral horn shown in Fig 3C [41]. Stained cells were
included in the counts if they had a diameter of20μm, specific labelling of the cytoplasm and
a spherical nucleus with clear nucleolus. Cells were imaged with the Leica DM2500 microscope
and the longest diameter of the cell body was measured using Q Imaging software. Counting
was done blind to genotype of the animal and left and right sides of the spinal cord sections
were counted separately. The 40 sections prior to the end of L5/start of L6 boundary were
included in the total counts of motor neurons. Confirmatory counts were performed on every
12th section within this region of the lumbar spinal cord using Nissl stained sections. When
counting was completed, the sums for the left and right side of the spinal cord sections
included for each animal were separated by genotype. Unpaired, one-tailed t-tests were per-
formed with GraphPad Prism (USA) to identify significant differences between genotype
groups, where p0.05.
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Western blot analysis. All animal tissues were collected upon euthanization of the animal
via cervical dislocation, snap-frozen in liquid nitrogen and stored at -80˚C. Tissues were then
weighed and ground in the presence of liquid nitrogen using a pestle and mortar, and incu-
bated on ice for 30 minutes in chilled RIPA buffer solution (150 mM sodium chloride, 1.0%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0, containing 1mM PMSF,
1mM sodium orthovanadate, 5mM sodium fluoride, and a mixture of protease inhibitors
(Roche). The samples were centrifuged at 4˚C for 15 minutes at 15,000rpm, the supernatants
were removed and used for protein quantification using the ‘BCA protein assay kit’ (Thermo
Scientific) and the final concentration was determined using a ‘Nanodrop ND-1000 Spectro-
photometer’ (Thermo Scientific) instrument. Samples were separated by 10% SDS/PAGE
using NuPAGE LDS loading dye (Life Technologies), proteins transferred from the gel onto a
PVDF membrane (Millipore) for 1 hour at a constant current of 80V, blocked in 5% non-fat
milk/TBS-Tween (0.1%), and incubated with primary antibody for 1 hour at room tempera-
ture followed by secondary antibody for a further hour. All antibodies were prepared in TBS/T
at the following dilutions: Anti-porcine DAO (Nordic, 1:2000); anti-beta tubulin (Abcam,
1:10000); goat anti-rabbit HRP (Bio Rad, 1:50000). Membranes were developed using
enhanced chemiluminescence (‘Amersham Hyperfilm ECL’ (GE Healthcare)).
Quantitative PCR for DAO expression. Spinal cord, brain and quadriceps muscle sam-
ples were pulverised under liquid nitrogen and the powder mixed with TRIzol reagent at a
ratio of 1ml TRIzol per 100mg tissue (quadriceps muscle) or 1ml per 50mg (brain and spinal
cord). Samples were extracted from tissue samples using a TRIzol protocol as supplied by the
manufacturers with the addition of an extra chloroform extraction step (1:1) after collection of
the aqueous phase. RNA was assessed via nanodrop to ensure good 260/280 and 260/230 ratios
(>1.9). Samples with 260/230 ratios lower than 1.9 were cleaned by a second round of isopro-
panol precipitation.
For cDNA synthesis, 800ng of RNA per reaction was reverse transcribed using the RTnano-
script2 kit (Primer Design) and final reactions were diluted 1/5 (empirically determined to be a
sufficient dilution to prevent cDNA synthesis reagents having any effect on subsequent PCR
efficiency). qPCR was performed in a CFX384 light cycler (Biorad) using PrecisionPLUS mas-
termix with SYBR green (Primer Design), with 10ul volumes of primers at a final concentration
of 500nM, and with 10-15ng cDNA per well. Cycling conditions: 2mins at 95˚C, then 50 cycles
of: 15sec 95 oC, 20sec 60˚C, 20sec 72 oC followed by a melt curve (60–95 oC in 0.5 degree steps).
The following primers were used:
hDAO qPCR Ex8F: CACCCATGACCCAGAGAGAG
hDAO qPCR Ex9R: ATTCTTCAGTGTGGGCTCCA
mDAO qPCR Ex8F: CCCATGATCCTAGCCTTGGT
mDAO qPCR Ex9R: GCTCCAGTTTACAGCAGCTC
Pak1ip1 was used as a reference gene in all tissues (Primer Design).
Determination of D-Amino Oxidase activity via spectrophotometric assay
DAO activity assays used a protocol modified from Tedeschi [14].
Non-transgenic (WT) mice and mice carrying the DAOR199W transgene were killed by cer-
vical dislocation and tissues harvested rapidly. 3–5 animals were used per genotype. Brains,
spinal cords and quadriceps muscles were flash-frozen and then pulverised under liquid nitro-
gen using a mortar and pestle before storage at -80˚C. Tissue homogenates were prepared by
combining powdered tissues with extraction buffer (75mM Sodium Pyrophosphate pH 8.5,
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supplemented with 0.5% NP40, complete protease inhibitor cocktail (Roche) and 1% phospha-
tase inhibitor cocktails 2 and 3 (Roche)) to a final concentration of approx. 50mg.ml-1 and
vortexing vigorously. Homogenates were incubated on ice for 10 minutes with occasional mix-
ing before removal of insoluble material by centrifugation (13krpm, at 4˚C in a benchtop
microfuge). Soluble protein fractions were collected and protein concentrations (typically 5-
10mg.ml-1) determined by DC protein assay (BioRad).
DAO spectrophotometric assays were performed in duplicate in flat-bottomed 96-well
plates (Corning), using an M200 Pro plate reader (TECAN) at room temperature. Soluble pro-
tein fractions (typically 100-200ug of soluble protein per well) were added to assay buffer
(75mM Sodium Pyrophosphate pH 8.5, 50mM D-serine, 20uM FAD, Horseradish Peroxidase
(1U.ml-1), ~1mM o-dianisidine–shaken well to oxygenate), mixed briefly, and absorbance
change at 436nM measure at approximately sixty second intervals for one hour. O-dianisidine
exhibits poor solubility in most aqueous solutions. For these assays, a stock solution at 33mM
was prepared in a 1:1 mix of DMSO and water, then added to 75mM sodium pyrophosphate
assay buffer to a final concentration of 1mM. The solution was incubated at room temperature
for 10 min to allow any insoluble dye to precipitate fully, then filtered before addition of FAD,
D-Serine and peroxidase. Crude tissue isolates typically exhibit a lag phase of 2–10 minutes
before reaching maximal rates, with rates subsequently lowering to a basal non-specific rate
after 20–30 minutes. Maximum rates were recorded and compared against a standard curve of
purified porcine DAO (loaded on the same plate).
Supporting information
S1 File. Text A. Methodology: Genotyping and Gait Analysis. Figure A. DAO enzyme
activity in spinal cord and brain from wild-type (WT) and DAOR199W transgenic mice
(R199W). Activity measured as mUnits/mg tissue/lysate in brain and spinal cord from wild-
type (WT) and DAOR199W transgenic mice (R199W). Figure B. D-serine immunoreactivity
in lumbar spinal cord from control and DAOR199W transgenic mice. A rabbit polyclonal
Anti-D-Serine antibody (Abcam) raised against D-serine cross-linked to BSA with glutaralde-
hyde was used at a dilution of 1 in 5,000 as previously described in detail [6]. Figure C. Serine
racemase immunoreactivity in lumbar spinal cord from control and DAOR199W transgenic
mice. A mouse monoclonal Anti-serine racemase antibody (BD Biosciences) was used at a
dilution of 1 in 1000 as previously described in detail [6].
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